300294.SHE China Resources Boya Bio pharmaceutical Group Co Ltd
- Market cap
- CNY 7.14B
- P/E
- -
- P/B
- 0.92x
- ROE
- 1.1%
- Dividend yield
- 2.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300294.SHE undervalued?
Graham numberThe Graham number of China Resources Boya Bio pharmaceutical Group Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China Resources Boya Bio pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for China Resources Boya Bio pharmaceutical Group Co Ltd yet.
China Resources Boya Bio pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound bone peptide, oxytocin, heparin sodium injection, posterior pituitary, and carbop…
Full company profileChina Resources Boya Bio pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
China Resources Boya Bio pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 947M | 1.39B | 2.39B | 2.91B | 2.51B | 2.65B | 2.76B | 2.65B | 1.73B | 2.05B | 1.13B |
| Gross Profit | 597M | 969M | 1.52B | 1.78B | 1.46B | 1.46B | 1.50B | 1.39B | 1.12B | 937M | 485M |
| Operating Income | 326M | 429M | 565M | 514M | 331M | 443M | 532M | 355M | 477M | 270M | -7.40M |
| EBITDA | 359M | 449M | 608M | 605M | 412M | 511M | 600M | 624M | 520M | 434M | 3.57M |
| Net Income | 272M | 357M | 469M | 426M | 260M | 345M | 432M | 237M | 397M | 113M | 83.1M |
| EPS | 1.02 | 0.89 | 1.11 | 1.00 | 0.61 | 0.79 | 0.86 | 0.47 | 0.79 | 0.22 | 0.16 |
| Balance Sheet | |||||||||||
| Total Assets | 2.42B | 3.67B | 5.07B | 5.26B | 5.16B | 7.62B | 8.03B | 7.83B | 8.40B | 8.63B | 8.25B |
| Total Liabilities | 287M | 1.19B | 1.30B | 1.27B | 966M | 701M | 748M | 508M | 913M | 1.16B | 801M |
| Shareholders' Equity | 2.09B | 2.43B | 3.70B | 3.91B | 4.11B | 6.83B | 7.19B | 7.32B | 7.49B | 7.44B | 7.45B |
| Cash & Short-term Investments | 422M | 502M | 1.19B | 569M | 754M | 4.28B | 4.73B | 5.32B | 3.50B | 3.23B | 750M |
| Total Debt | 22.1M | 527M | 607M | 623M | 330M | 35.6M | 35.4M | 23.5M | 7.17M | 333M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 199M | -23.8M | 34.9M | -115M | 719M | 1.35B | 596M | 642M | 300M | 117M | - |
| Capital Expenditure | 300M | 238M | 114M | 88.6M | 143M | 68.1M | 138M | 87.5M | 198M | 535M | 465M |
| Free Cash Flow | -101M | -262M | -79.0M | -203M | 576M | 1.28B | 458M | 554M | 102M | -419M | -558M |
| Ratios | |||||||||||
| ROE | 13.0% | 14.7% | 12.7% | 10.9% | 6.3% | 5.0% | 6.0% | 3.2% | 5.3% | 1.5% | 1.1% |
| ROA | 11.2% | 9.7% | 9.2% | 8.1% | 5.0% | 4.5% | 5.4% | 3.0% | 4.7% | 1.3% | 1.0% |
| Net Profit Margin | 28.7% | 25.6% | 19.7% | 14.7% | 10.3% | 13.0% | 15.7% | 9.0% | 22.9% | 5.5% | 7.4% |
| Debt to Equity | 0.01x | 0.22x | 0.16x | 0.16x | 0.08x | 0.01x | 0.00x | 0.00x | 0.00x | 0.04x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
China Resources Boya Bio pharmaceutical Group Co Ltd dividends
- Dividend yield
- 2.19%
- Forward dividend
- 0.22 CNY
- Payout ratio
- 138.7%
- Ex-dividend date
- May 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 156M | 0.31 | 138.7% |
| 2024 | CNY 232M | 0.46 | 58.5% |
| 2023 | CNY 135M | 0.27 | 56.8% |
| 2022 | CNY 75.6M | 0.15 | 17.5% |
| 2021 | CNY 27.7M | 0.06 | 8.0% |
| 2020 | CNY 63.9M | 0.15 | 24.6% |
| 2019 | CNY 65.0M | 0.15 | 15.3% |
| 2018 | CNY 102M | 0.24 | 21.7% |
| 2017 | CNY 39.6M | 0.10 | 11.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on May 26, 2017.
Who owns China Resources Boya Bio pharmaceutical Group Co Ltd
- Insiders 33.13%
- Institutions 13.73%
- Public & others 53.14%
- Shares outstanding 504M
- Free float 268M
China Resources Boya Bio pharmaceutical Group Co Ltd company profile
- Company name
- China Resources Boya Bio pharmaceutical Group Co Ltd
- Ticker
- 300294.SHE
- ISIN
- CNE100001FF1
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Mar 8, 2012
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,947
- Fiscal year end
- December
- Address
- No. 333, Huiquan Road, Fuzhou, China, 344000
- Phone
- 86 79 4822 4549
- Website
- china-boya.com
About China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound bone peptide, oxytocin, heparin sodium injection, posterior pituitary, and carboprost tromethamine injection. In addition, it engages in research, development, production, and sales of anti-infective, diabetes, and cardiovascular drugs. The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co.,Ltd. The company was founded in 1993 and is based in Fuzhou, China.
China Resources Boya Bio pharmaceutical Group Co Ltd management
2- Mr. Yuxuan PanCFO, Board Secretary & Director · born 1984
- Zi He WangAccounting Supervisor